Project Scope | |||||
This | project Project team will create a White Paper with recommendations for | treatment emergent definitionsTreatment Emergent Definitions, with a focus on Phase 2-4 clinical trials. | This White Paper will build upon a White Paper that outlines results from a survey on current practices, indicating variation that can likely be reduced. | Recommendations will | be be based on the desired end-in-mind, and may or may not be consistent with current practices. |
| Project Leads | Emails |
|---|
Mary Nilsson
nilsson_mary-e@lilly.com
William Palo, Abbvie |
Nicola Newton, PHUSE Project |
Assistant |
|
|---|
|
|---|
|
|---|
|
|---|
| ||
|---|---|---|
|
Objectives & Deliverables | Timelines |
|---|---|
White Paper - Recommended Definition of Treatment-Emergent Adverse Events in Clinical Trials' | Q3 2024 |